Drug Trial Radar · NCT05619783
Extension Study Evaluating The Safety And Tolerability of AMX0035
Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
352
Actual
Start
Dec 29, 2022
Primary completion
Oct 16, 2024
Study completion Oct 30, 2024
Sponsor
- Lead sponsor
- Amylyx Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the safety and tolerability of AMX0035 over 108 weeks of open label treatment for participants previously enrolled in Study A35-004 (PHOENIX).
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
AMX0035Drug
Combination of 3 g phenylbutyrate and 1 g taurursodiol
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the Incidence of Treatment-Emergent Adverse Events during treatment with AMX0035Time frame: 108 weeks
Locations
46 sites in 11 countries. Site status is shown where the registry gives one.
University Hospitals Leuven
Leuven, Belgium
Hospices Civils de Lyon Hôpital Neurologique Pierre Wertheimer Cellule Mutualisée de Recherche Clinique (CMRC)
Bron, France
Hopital Gabriel Montpied Service de Neurologie
Clermont-Ferrand, France
CHRU de Lille - Hôpital Roger Salengro
Lille, France
CHU de Limoges - Hôpital Dupuytren
Limoges, France
Hôpitaux Universitaires de Marseille Timone
Marseille, France
CHU de Montpellier
Montpellier, France
Gui de Chauliac
Montpellier, France
CHU Nice
Nice, France
Hôpital de la Salpêtrière
Paris, France
Le Centre Hospitalier Régional Universitaire de Tours
Tours, France
Uniklinikum Dresden
Dresden, Germany
Hannover Medical School
Hanover, Germany
Jena University Hospital
Jena, Germany
Medizinische Fakultät Mannheim der Universität Heidelberg
Mannheim, Germany
University Medical Center Rostock
Rostock, Germany
Ulm University Medical Centre
Ulm, Germany
Trinity College Dublin/Beaumont Hospital
Dublin, Ireland
Università degli Studi di Bari Aldo Moro
Bari, Italy
Centro Clinico NEMO
Milan, Italy
IRCCS - Ospedale San Raffaele
Milan, Italy
University of Milan Medical School
Milan, Italy
IRCCS - Istituto Auxologico italiano
Milan, Italy
Azienda Ospedaliero Universitaria Di Modena
Modena, Italy
Università degli Studi della Campania Luigi Vanvitelli
Naples, Italy
University of Padua
Padova, Italy
Università degli Studi di Bari Aldo Moro
Tricase, Italy
University of Torino
Turin, Italy
University Medical Center Utrecht
Utrecht, Netherlands
Centrum Medyczne Linden
Krakow, Poland
City Clinic Warsaw
Warsaw, Poland
Centro Hospitalar Universitário Lisboa-Norte
Lisbon, Portugal
Hospital del Mar
Barcelona, Spain
Hospital Universitari de Bellvitge-IDIBELL
Barcelona, Spain
Hospital Universitario de Basurto
Bilbao, Spain
Hospital San Rafael
Madrid, Spain
Biodonostia Health Research Institute; Hospital Universitario Donostia
San Sebastián, Spain
Hospital Universitario y Politécnico La Fe
Valencia, Spain
Karolinska Institutet
Stockholm, Sweden
Umeå University Hospital
Umeå, Sweden
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.